Conference Presentation

Nektar to present 36-week rezpegaldesleukin maintenance data in H2 2026

REZOLVE-AD's Week 16 primary readout already showed EASI reduction versus placebo; the pending presentation extends that signal through 36 weeks as Nektar moves the drug into Phase 3.

By AppliedXLJuly 14, 2026Trial NCT06136741

Executive Summary

Nektar Therapeutics is set to present longer-term maintenance data from its Phase 2b atopic dermatitis trial of rezpegaldesleukin at a medical conference in the second half of 2026, building on a primary result already reported at an earlier dermatology meeting.
The trial's primary endpoint already showed an EASI improvement over placebo at the earlier readout, so the new data will test whether that effect holds through a longer treatment window rather than establish a new signal from scratch.
Nektar has already committed to advancing rezpegaldesleukin into a Phase 3 atopic dermatitis program, so the maintenance data extends the evidence base underneath a decision the company has already made operationally.
Rezpegaldesleukin remains the only IL-2 receptor agonist in Phase 2 testing for this indication, so the readout has no direct mechanistic comparator to benchmark against in atopic dermatitis.

The presentation

Nektar Therapeutics has a planned scientific conference presentation of 36-week maintenance data from REZOLVE-AD, the Phase 2b trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis (NCT06136741), scheduled for a window running from July 1 through December 31, 2026. The trial's registered primary endpoint is mean percent change in the Eczema Area and Severity Index, or EASI, a standard atopic dermatitis severity score, from baseline at Week 16. Nektar+1

Probability of Success

Endpoint Met75%

Completes82%

Clinical Significance50%

Regulatory59%

What already read out

That Week 16 primary analysis has already been reported. Nektar presented data from the 393-patient trial at the 2026 American Academy of Dermatology Annual Meeting on March 28, 2026, describing a consistent reduction in mean EASI scores versus placebo over 16 weeks and comparable EASI-75 and EASI-90 response rates between arms. The company's fourth-quarter 2025 disclosure called the Phase 2 results in atopic dermatitis and alopecia areata "successful and transformative," and Chief Executive Officer Howard W. Robin said the 52-week treatment data "provide hope that complete clearance of disease could be possible for patients with monthly and quarterly maintenance dosing of rezpegaldesleukin". The upcoming H2 2026 presentation is positioned to extend that same trial's follow-up to 36 weeks, testing whether the Week 16 effect is durable under maintenance dosing rather than introducing a new endpoint. Nektar

Registry mechanics

REZOLVE-AD has moved through two primary-completion-date revisions since its registration, from May 30, 2025 to June 1, 2025 and then to May 6, 2025, alongside a status shift from Recruiting to Active, not recruiting in January 2025 as enrollment closed at target. Enrollment held flat at 396 patients through that period, a routine outcome for a trial reaching its planned enrollment ceiling rather than a shortfall. The trial carries 10 experimental arms against 2 placebo comparator arms and tracks 16 secondary endpoints spanning EASI-50, EASI-75, EASI-90, SCORAD, and itch response through week 104, the broader dataset the 36-week presentation likely draws from. NCT06136741

The Phase 3 readthrough

Nektar has already registered a Phase 3 rezpegaldesleukin atopic dermatitis trial, NCT07690371, with a completion date of May 2028, built on the same Week 16 EASI endpoint architecture used in REZOLVE-AD. That sequencing means the 36-week maintenance data functions less as a stand-alone catalyst and more as supporting evidence for a Phase 3 program the company has already committed to advance. Rezpegaldesleukin is the only Phase 2 asset targeting the IL-2 receptor in moderate-to-severe atopic dermatitis, with no other industry trial sharing both its target and its indication at this stage of development, leaving the mechanism without a direct precedent to benchmark the maintenance data against in this specific disease setting. Nektar

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.